Oral Radiation Nuclear Decorporation Agents

某些内部放射性污染物的去除可以通过施用螯合剂来实现，所述螯合剂可以优先与体内的放射性核素络合并增加它们的清除率，从而减少辐射暴露。喷替酸（二亚乙基三胺五乙酸）钙三钠（Ca-DTPA）和喷替酸（二亚乙基三胺五乙酸）锌三钠（Zn-DTPA）已被证明可有效治疗放射性核素（如钚、镅或铥）的内部污染。然而，由于DTPA必须通过静脉注射或雾化器给药，因此在大规模伤亡情况下没有用处。该合同促进了更适合大规模伤亡情况的口服形式的Ca-DTPA和Zn-DTPA的开发。

The removal of certain internal radioactive contaminants can be accomplished by administering chelating agents that can preferentially complex with radionuclides in the body and increase their rate of clearance, thereby decreasing radiation exposure. Pentetate (diethylenetriaminepentaacetate) calcium trisodium (Ca-DTPA) and pentetate (diethylenetriaminepentaacetate) zinc trisodium (Zn-DTPA) have been shown to be effective in treating internal contamination with radionuclides such as plutonium, americium, or curium. However, because DTPA must be given intravenously or by nebulizer, it is not useful in a mass casualty situation. This Contract advances the development of oral forms of Ca-DTPA and Zn-DTPA that are more suitable for a mass casualty situation.